Is Octreotide Benefitial in Patients with Metastatic Gastroenteropancreatic (GEP) and Hepatobiliary Neuroendocrine Carcinoma (NEC)?
#608
Introduction: Neuroendocrine carcinomas (NECs) of the gastroenteropancreatic (GEP) and hepatobiliary (HB) tract are rare and a heterogenous group of malignancies. Octreotide showed the anti-tumor activity in well-differentiated metastatic midgut neuroendocrine tumors (NETs).
Aim(s): It has not been evaluated whether octreotide in NEC affects survival outcome or not.
Materials and methods: We analyzed 17 patients (6 ; HB- and 11 ; GEP- tract) with metastatic NEC who had been diagnosed between January 2009 and June 2012. All patients had one or more cytotoxic chemotherapy and nin had received octreotide as a single agent (n=3) or combination of cytotoxic chemotherapy (n=6) during treatment period.
Conference: 10th Annual ENETSConcerence (2013)
Presenting Author:
Authors: Kim S,
Keywords: NEC, octreotide, GEP, HB,
To read the full abstract, please log into your ENETS Member account.